[{"address1": "455 East Medical Center Boulevard", "address2": "Suite 300", "city": "Houston", "state": "TX", "zip": "77598", "country": "United States", "phone": "281 671 5150", "website": "https://www.fibrobiologics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas.", "fullTimeEmployees": 10, "companyOfficers": [{"maxAge": 1, "name": "Mr. Peter  O'Heeron", "age": 59, "title": "Founder, Chairman & CEO", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 950723, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark C. Andersen C.F.A., CPA, M.B.A.", "age": 51, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 461877, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hamid  Khoja Ph.D.", "age": 53, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 423119, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 13.0, "open": 12.78, "dayLow": 9.0, "dayHigh": 12.7375, "regularMarketPreviousClose": 13.0, "regularMarketOpen": 12.78, "regularMarketDayLow": 9.0, "regularMarketDayHigh": 12.7375, "volume": 107055, "regularMarketVolume": 107055, "averageVolume": 150414, "averageVolume10days": 74280, "averageDailyVolume10Day": 74280, "bidSize": 1000, "askSize": 800, "marketCap": 402472480, "fiftyTwoWeekLow": 6.53, "fiftyTwoWeekHigh": 46.0, "fiftyDayAverage": 12.219048, "twoHundredDayAverage": 12.219048, "currency": "USD", "enterpriseValue": 288077888, "floatShares": 24692347, "sharesOutstanding": 32492100, "dateShortInterest": 1707955200, "heldPercentInsiders": 0.30412, "shortRatio": 0.36, "impliedSharesOutstanding": 44276400, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -19058000, "enterpriseToEbitda": -32.581, "52WeekChange": -0.25714284, "SandP52WeekChange": 0.28866112, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "FBLG", "underlyingSymbol": "FBLG", "shortName": "FibroBiologics, Inc.", "longName": "FibroBiologics, Inc.", "firstTradeDateEpochUtc": 1706797800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "6752a379-a671-33c4-8602-9f32d42c8f6a", "messageBoardId": "finmb_1758633149", "gmtOffSetMilliseconds": -18000000, "currentPrice": 9.09, "recommendationKey": "none", "totalCash": 9163000, "totalCashPerShare": 0.282, "ebitda": -8842000, "totalDebt": 1888000, "quickRatio": 0.998, "currentRatio": 1.003, "debtToEquity": 150.678, "returnOnAssets": -0.66753995, "freeCashflow": 3831500, "operatingCashflow": -6401000, "financialCurrency": "USD", "trailingPegRatio": null}]